Monitoring Agency Report

November 05, 2026 To, To, The Listing Department, The Listing Department BSE Limited, National Stock Exchange of India Ltd., Phiroze Jeejeebhoy Towers, Exchange Plaza, Dalal Street, Bandra Kurla Complex, Bandra (East), Mumbai – 400001 Mumbai – 400051 Scrip code: 544889 Symbol: SYMBIOTEC Sub.: Monitoring Agency Report issued by CARE Edge Ratings for the utilisation and application of funds raised through the Initial Public Offer (IPO) of the Company for the quarter ended September 30, 2026 Dear Sir / Madam, Pursuant to Regulation 32(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with Regulation 41(4) of the SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018, we have enclosed herewith the Monitoring Agency Report issued by the CARE Edge Ratings, Monitoring Agency, appointed by the Company for the utilisation and application of funds raised through the Initial Public Offer (IPO) of the Company for the quarter ended September 30, 2026. The above information is being uploaded on the website of the Company viz. https://investor.symbiotec.com/announcements Thanking You, Sincerely, for Symbiotec Pharmalab Limited Salil Jain Company Secretary and Compliance Officer Membership No. A41610 Encl: As above Registered Office & Works: Symbiotec Pharmalab Limited (Formerly known as Symbiotec Pharmalab Pvt. Ltd.) 385/2, Pigdamber, Rau, Mhow, Indore - 453331, Madhya Pradesh, India Tel. No.: +91-731-6676405-406 Fax: +91-731-4201222, Email ID : symbiotec@symbiotec.com, Website : www.symbiotec.com CIN: U24232MP2002PLC015293 Monitoring Agency Report No. CARE/ARO/GEN/2026-27/1210 The Board of Directors Symbiotec Pharmalab Limited 385/2, Pigdamber, Rau, Indore Madhya Pradesh 453331 November 05, 2026 Monitoring Agency Report for the quarter ended Sept. 30, 2026 -in relation to the IPO of Symbiotec Pharmalab We write in our capacity of Monitoring Agency for the IPO for the amount aggregating to Rs.150 crore of the Company and refer to our duties cast under 41 of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations. In this connection, we are enclosing the Monitoring Agency Report for the quarter ended Sept. 30, 2026 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated August 06, 2026. Request you to kindly take the same on records. Thanking you, Yours faithfully, Dhruv Shah Assistant Director Dhruv.Shah@careedge.in Report of the Monitoring Agency Name of the issuer: Symbiotec Pharmalab Limited For quarter ended: Sept. 30, 2026 Name of the Monitoring Agency: CARE Ratings Limited (a)Deviation from the Objects: Nil (b)Range of Deviation:Not applicable Declaration: We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intendedto or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013. The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict ofinterest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity. We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where s Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no respons Signature: Name and designation of the Authorized Signatory: Dhruv Shah Designation of Authorized Person/Signing Authority: Assistant Director CaEdger e RATINGS Souorfic nef or/mc aetritoinfications Commeonftt hse Commeonftt hse Particulars Reply consibdyMe orneidt Aogreinfncogyr Boaorfd MonitAogreinncgy prepaorfra etpioornt Directors Itsh earneoy t hreerl eivnafnotr tmhamataitmyo a nt erially No ManageCmeerntti ficate Noc omment None afftehcdete cimsaikoionnft g hi en vestors? *CharAtcecroeudcn etratnitff rioMcmaa hteCesS ho la&Cn ok(.ip ereerv iaeuwdefidit rv mi)Cd Aec ertidfaitNceoadvt eem 2b2,e0 r2 6. #Whemraet edreivailma atbiyeo d ne fitnome eda n: a)Deviiatnth ioeob nj eocrpt usr pfooswreh sit chhfe u nhdasvb ee erna ised b)Deviiatnth iaeom no uonfft u nadcst uuatlillbyiym z oertdeh a1n0o %ft haem ount pirtnoh joefe fcdetorec du ments. 4)Detoafoi bljset cobt ems o nitored: (i) Coosfto bje-cts CommentthBseo oaorffDd i rectors Souorfic nef or/m atiOorni gcionsatl Commeonft s Partiocf-u lars Sr. Item certifciocnastibidyoe nr(sea pdse t rh Oeff er ReviCsoesdt the Reasfoocnro st Proposed firm No Head MonitAogreinfncogyr Document)i Rns C.r oreM onitoring revisiofni naonpctiinogan r rangements prepaorfra etpioornt inC�r ore Agency made Prepayamnedn/rtoe rp ayment, ifnu olril pn a rotfa, lo lra 1 portoifco enr toauitns tanOdfifdneogrc ument 112.5N0oa tp plicabNliel None None None borroawvianibglysoe udr Company 2 Genecroarlp opruartpeo seOsf fdeorc ument 29.5N3o atp plicabNliel None None None Offreerl aetxepde inns es 3 Offdeorc ument 7.98N oatp plicabNliel None None None relattoti hoFenr eIsshs ue Total 150.00 Disclaimers to MA report: a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as ). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like internal auditor which is peer reviewed audit firm appointed by the Issuer believed by it to beaccurate and reliable. c)Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report. d)The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from internal auditor which is peer reviewed audit firm, lawyers, chartered engineers or other experts, and relies [Showing first 8,000 characters — download PDF for full document]